Medical device tax: Zoll CEO Packer says levy will lead to permanent job losses and higher healthcare costs


Rick Packer may have orchestrated a dazzling $2.3 billion acquisition of Zoll Medical (NSDQ:ZOLL) by Japan’s Asahi Kasei Corp. (TYO:3407) this spring, but he still sees the medical device tax as a major stumbling block for both his company and the med-tech industry in general.

The Zoll CEO told a forum in Boston this week that he still finds the tax infinitely frustrating, even 2 years after it first started making headlines as part of President Barack Obama’s healthcare reform law.

"It’s hard for everybody in the device industry, because all of the new patients that many people are promising us don’t kick in for a few years down the road. But the tax starts in 2013," Packer said. "For most of my business, which is a capital equipment business, nobody needs a 2nd defibrillator. There aren’t going to be more heart attacks because of having universal healthcare, so there is no upside to my business from universal healthcare. There is only this tax, and it’s absolutely going to mean fewer jobs, full stop. There’s no question about that."

Zoll, which became a wholly owned subsidiary of the Asahi Kasei Group after the deal closed last month, will continue to be led by current management and with all current business units and operations intact, according to an SEC filing. Nevertheless, Packer said the device tax will force the company to tighten its belt.

"We will move production offshore, which will mean fewer jobs at Zoll. We will do that because we can lower our cost basis and that lower cost basis will lower the tax. It will mean fewer engineers at Zoll, because we will not be likely able to afford them. It will mean a general hiring freeze over the next 18 months or so while we deal with this tax," he said. "In the long run, what every company will do is pass the cost along to our customers. The basic profitability of the industry will raise to its normal level, based on competitive issues, not tax levels. We know that that’s going to happen

"In the long run, you’re going to have the worst case," Packer said. "You’re going to have permanent job loss and higher cost to the healthcare system. It is clearly not my favorite piece of legislation. I do think we have a chance to get it altered, moderated or repealed. We will not execute anything at Zoll until after the fall election. We’ll see what the real lay of the land is then. After that, we will move very quickly to reduce our costs."

Packer has long been a vocal and visible opponent of the tax.

In 2010, Zoll made national news when now-Sen. Scott Brown (R-Mass.) made opposition to the tax a mainstay of his campaign to take the late Sen. Ted Kennedy’s seat during a visit to Zoll’s Chelmsford, Mass., headquarters. Brown picked up many of his talking points against the tax during that visit.

It was then, Brown told in a recent interview, that Packer told him that a 2.3% excise tax on revenues would wipe out the company’s annual profits, a data point that Brown continues to use as he sells his move to repeal to the tax.

"I remember learning about it when I was running," Brown told us. "I went to Zoll Medical and they were talking about how the device tax could potentially represent their entire net profit."

His first thoughts were,"Wow. Now that puts it in real terms," Brown said.

RSS From Medical Design & Outsourcing

  • GlobTek presents its latest level VI AC/DC adapter and connverter
    T-43086-WWVV-X.X-Q Model is an addition to GlobTek’s Level VI compliant GT-43086 family and represents GlobTek’s 6 Watt wall plug-in series of AC/DC adapters (power supplies and chargers) with International Interchangeable blades. GlobTek’s changeable input blade system with individual field replaceable input plugs, including: North America and Japan NEMA 1-15P, Australian, UK BS 1363, European CEE […]
  • Sanmina’s familiarity with FDA gets skin treatment product to market fast
    The medical market for cosmetic devices is booming. However, quickly launching new products to meet demand is becoming more challenging because device manufactures face increased regulatory scrutiny. To help meet regulatory requirements, aesthetic and other medical-device OEMs are partnering with electronics manufacturing services (EMS) companies that also offer expertise with the FDA filings necessary to […]
  • Fluid connectors and quick disconnects for IVD equipment from CPC
    Colder Products Company (CPC) offers thousands of tubing connectors, quick disconnects and fittings for smart fluid handling in IVD and analytical equipment. Non-spill connectors speed testing throughput by eliminating drips, preventing air inclusion and increasing operator safety. Panel mount connectors can be added to existing equipment or bottle caps to provide secure, leak-free connections. Puncture […]
  • 310 Watt desktop medical power supply meets efficiency level VI requirements
    Power Partners releases a new 310 Watt medical grade desktop power supply from their PEAMD Series of AC and DC adapters. The 310 Watt unit is packed for ideal performance inside a compact case measuring 7.8 x 4 x 2 in. with a weight of only 3 lbs. The PEAMD310 Series is approved to the latest […]
  • Saelig introduces Multiple Instrument System MIS4 universal test system
    Saelig Company has introduced the ABI Electronics’ Multiple Instrument Station MIS4, an all-in-one testing tool that provides all commonly required test instruments in one compact programmable hardware module, mounted in a compact case or installed in a PC-drive bay. Controlled by ABI’s sophisticated SYSTEM 8 Ultimate PC software with a simple yet programmable operator interface, […]
  • AssurX announces document management software update for small to mid-size companies in FDA regulated industries
    AssurX, an enterprise quality management, risk and regulatory compliance solution provider, announces the release of the latest update to their AssurX document management software. The document management solution provides a cost-effective solution for small to medium sized companies faced with streamlined operations and is fully compliant for FDA regulated industries. Ideal solution for small to […]
  • Saelig presents new Amplicon Impact-R 1100F series computer
    Saelig Company announces the Amplicon Impact-R 1100F series, a fanless system powered by the Intel ATOM D2550 processor. Configured with a high performance 2.5 in. MLC Solid State Drive (SSD), the Impact-R 1100F series is a silent controller system. With options for multiple serial communication ports, the Impact-R 1100F can offer up seven DB9 connections […]
  • Gerresheimer to acquire Centor
    Gerresheimer AG, a partner to the global pharmacy and healthcare industry, will further extend its pharmaceutical packaging business with the acquisition of Centor. Gerresheimer has reached an agreement with Nemera Development S.A. to acquire 100% of the share capital of Centor US Holding. “Centor is the highly profitable market leader for plastic vials and closures in […]
  • Methods Machine Tools presents the new Nakamura-Tome NTRX-300
    Methods Machine Tools, a developer of precision machine tools and automation, has introduced the new Nakamura-Tome NTRX-300, a multitasking turning center featuring complete parts machining in one operation, with a built-in load and unload automation system and advanced operator recognition management software. The NTRX-300 features true opposing twin spindles: an 8 in. A2-6 25 HP or […]
  • MSC Apex Diamond Python and Smart Midsurface speeds modeling to validation
    MSC Software announced a new release of MSC Apex, the company’s award-winning next generation Computer Aided Engineering (CAE) platform. The MSC Apex Diamond Python release introduces: · The fourth release of MSC Apex Modeler is a CAE Specific direct modeling and meshing solution that streamlines CAD clean-up, simplification and meshing workflow. New in this release is […]
  • Quality Metrics: FDA’s plan for a key set of measurements to help ensure manufacturers are producing quality medications
    Editor’s Note: This article is written by Ashley Boam and Mary Malarkey from the “FDA Voice” blog. Boam is an FDA’s acting Director of the Office of Policy for Pharmaceutical Quality, the Office of Pharmaceutical Quality and the Center for Drug Evaluation and Research. Malarkey is an FDA’s Director if the Office of Compliance and Biologics Quality […]

Leave a Reply